11/06/2026
On a bright (pun intended!) and sunny day in May, Sprint Bioscience had the pleasure of visiting MAX IV Laboratory in Lund, a place that truly feels like an extension of our labs in Flemingsberg. In this article by BioStock - Connecting Innovation & Capital🔗https://biostock.se/en/2026/06/sprint-bioscience-forskar-med-en-av-varldens-ljusstarkaste-rontgenkallor/ you can read more about it.
For Sprint Bioscience, MAX IV plays a central role in our ability to push the boundaries of structure-based drug discovery. Access to a world-leading synchrotron light source, with its exceptional brightness and precision, enables us to generate high-quality structural data that directly accelerates our drug development programs. But beyond the technology itself, the collaboration has strengthened how we work.
By combining structural biology with fragment-based approaches, we can explore multiple chemical tracks in parallel and rapidly identify molecules with promising drug-like properties. This way of working remains relatively rare, not only in Sweden but globally, and gives us a strong strategic advantage.
Rather than relying on traditional high-throughput screening (HTS), we are built on the principle of “designing right from the start.” Structural insights allow us to understand how molecules interact with their target proteins at the atomic level, guiding every iteration in our process. Between each cycle, crystallography helps us confirm: are we on the right path, and are we optimizing in the best possible way? This results in higher-quality programs. When we know exactly how a molecule binds to its target, we can intelligently refine and optimize it. The outcome is not just a single molecule, but a comprehensive package, including lead series, backup series, and valuable intellectual property, that significantly strengthens the value for our partners.
We are proud to collaborate with MAX IV as part of a uniquely strong Swedish innovation ecosystem, where cutting-edge infrastructure, science, and industry come together to drive the next generation of therapies. Our structural biologists and proteincrystallographers Lionel Trésaugues and Wimal Ubhayasekera lead our way forward.
Thanks to MAX IV’s Industrial Relations Office team for an insightful and engaging visit!
